AMRN Amarin Dashboard

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Company profile

Ticker

AMRN

Exchange

NASDAQ

Website

www.amarincorp.com/

CEO

John Thero

Incorporated

United Kingdom

Location

Ireland

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...

Former names

AMARIN PHARMACEUTICALS PLC, ETHICAL HOLDINGS PLC

SEC CIK

0000897448

Corporate docs

Articles of Incorporation & Bylaws

AMRN stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Cramer Weighs In On Paysafe, Xilinx And More

15 Apr 21

On CNBC's "Mad Money Lightning Round," Jim Cramer said Keysight Technologies Inc (NYSE: KEYS) has been just red hot and he really likes it.

TENX: HELP Results & New Asset to Boot

14 Apr 21

By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT

50 Biggest Movers From Yesterday

14 Apr 21

Gainers

12 Health Care Stocks Moving In Tuesday's Intraday Session

13 Apr 21

The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug

13 Apr 21

Press releases

Pro users get this 30m faster

VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021

17 Apr 21

Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy Effect on coronary plaque stabilization reported to be significant at 9 months and

Amarin Announces CEO Succession Plan

12 Apr 21

John Thero to Retire as President and CEO on August 1, 2021 Board Appoints Karim Mikhail, Current SVP and Head of Commercial for Europe, as Successor DUBLIN, Ireland and BRIDGEWATER, N.J., April 12, 2021 (GLOBE

Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication

6 Apr 21

Reimbursement dossiers for first 10 countries to be filed in coming months 150 people hired and on-track to be deployed by mid-Q2 2021 supplemented by digital outreach and medical education programs with initial top

Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk

30 Mar 21

HLS Therapeutics Announces that Icosapent Ethyl (Vascepa®) is Included in the 2021 Canadian Cardiovascular Society (CCS) Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults

29 Mar 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

25 Feb 21

17 Apr 21

31 Dec 21

Financial summary

Financial statements Chart AMRN financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Amarin earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	186.96M	186.96M	186.96M	186.96M	186.96M	186.96M
Cash burn (monthly)	6.75M	38.14M	(positive/no burn)	1.58M	12.77M	1.81M
Cash used (since last report)	24.12M	136.3M	n/a	5.65M	45.66M	6.48M
Cash remaining	162.85M	50.67M	n/a	181.32M	141.31M	180.49M
Runway (months of cash)	24.1	1.3	n/a	114.8	11.1	99.6

Beta Read what these cash burn values mean

Recent insider trades

AMRN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
31 Mar 21	Joseph T Kennedy	Ordinary Shares	Payment of exercise	Dispose F	No	No	6.37	3,803	24.23K	304,192
31 Mar 21	Joseph T Kennedy	Ordinary Shares	Option exercise	Aquire M	No	No	0	3,610	0	307,995
31 Mar 21	Joseph T Kennedy	Ordinary Shares	Option exercise	Aquire M	No	No	0	1,805	0	304,385
31 Mar 21	Joseph T Kennedy	Ordinary Shares	Option exercise	Aquire M	No	No	0	1,805	0	302,580
31 Mar 21	Joseph T Kennedy	RSU Ordinary Shares	Option exercise	Dispose M	No	No	0	3,610	0	18,050
31 Mar 21	Joseph T Kennedy	RSU Ordinary Shares	Option exercise	Dispose M	No	No	0	1,805	0	9,025
31 Mar 21	Joseph T Kennedy	RSU Ordinary Shares	Option exercise	Dispose M	No	No	0	1,805	0	9,025
31 Mar 21	Steven B Ketchum	Ordinary Shares	Payment of exercise	Dispose F	No	No	6.37	3,128	19.93K	440,230
31 Mar 21	Steven B Ketchum	Ordinary Shares	Option exercise	Aquire M	No	No	0	3,056	0	443,358
31 Mar 21	Steven B Ketchum	Ordinary Shares	Option exercise	Aquire M	No	No	0	1,528	0	440,302

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

AMRN institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

37.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	242	259	-6.6%
Opened positions	43	38	+13.2%
Closed positions	60	59	+1.7%
Increased positions	42	82	-48.8%
Reduced positions	86	65	+32.3%

13F shares	Current	Prev Q	Change
Total value	1.08B	664.15M	+62.6%
Total shares	148.39M	147.16M	+0.8%
Total puts	5.7M	6.87M	-16.9%
Total calls	7.21M	6.11M	+18.0%
Total put/call ratio	0.8	1.1	-29.6%

Largest owners	Shares	Value	Change
Baker Bros. Advisors	27.99M	$136.88M	-12.6%
Eversept Partners	15.94M	$77.97M	+49.7%
BVF	10.76M	$52.62M	+878.3%
Boxer Capital	6M	$29.34M	-14.3%
Avoro Capital Advisors	6M	$29.34M	0.0%
MS Morgan Stanley	5.98M	$29.22M	+198.3%
Grosvenor Holdings, L.L.C.	5.89M	$28.8M	+8.7%
SCP Investment	5.5M	$26.9M	+120.0%
Clearbridge Advisors	4.63M	$22.62M	+56.4%
Rock Springs Capital Management	4.2M	$20.51M	-3.6%

Largest transactions	Shares	Bought/sold	Change
BVF	10.76M	+9.66M	+878.3%
Eversept Partners	15.94M	+5.29M	+49.7%
Artisan Partners Limited Partnership	0	-5.19M	EXIT
Avidity Partners Management	0	-4.51M	EXIT
Baker Bros. Advisors	27.99M	-4.03M	-12.6%
MS Morgan Stanley	5.98M	+3.97M	+198.3%
D. E. Shaw & Co.	3.85M	-3M	-43.8%
SCP Investment	5.5M	+3M	+120.0%
First Light Asset Management	0	-2.24M	EXIT
DG Capital Management	2.22M	+2.22M	NEW

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Ionis Pharmaceuticals • Astrazeneca • Novartis • Intercept Pharmaceuticals • Acasti Pharma • Cardax • Abbvie • Matinas Biopharma • NeuroBo Pharmaceuticals

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: affiliate, ahead, Aid, AMPLIFY, angiographic, answer, Arabia, argued, attitude, Bahrain, beneficiary, Benjamin, Biden, biosimilar, boxed, Brigham, burdensome, CABG, CADTH, CAL, calcium, capita, career, CD, certiorari, checking, CHMP, CID, clear, cohesively, commenrcialization, composed, consequentially, contact, contacting, convince, coordinated, coordination, DEF, Defintiion, dense, destabilized, DH, diagnosed, diligently, discouraged, distancing, distracting, divergence, doctor, DOJ, drop, dying, EC, economy, Edding, elderly, emia, emphasize, emphasizing, ensued, era, excellence, Fake, fewer, fibrofatty, forthcoming, Franc, FY, FYs, gated, gender, geographically, globe, Grafenauweg, grafting, hall, hard, Harvard, height, heightened, hereinafter, hereto, honor, honoring, hope, hourly, hypercholesterol, IA, IIb, impeding, inexpensive, infected, infection, inflow, influenza, Inilne, input, Inspector, intelligence, Irelnad, irrespective, ischemic, Italy, Justice, justified, Lable, LAP, lenient, leverage, Liaison, Linkbase, LYPDISO, manmade, MDCT, medium, metformin, MFN, modest, morale, multidetector, multifactorial, multivariable, NMPA, Nordic, OIG, OMEMI, OPML, optimistic, orientation, overly, overturned, pandemic, paused, PCI, PD, Peterson, postulated, precautionary, predominately, prostate, race, reaccelerate, reactive, receent, rehearin, reinforcement, reinstitution, religion, remote, remotely, renumeration, reportedly, reprioritization, respitory, restraining, resume, resumed, resumption, retention, rewarding, rightsized, Saudi, saving, scan, Schema, School, score, Secretary, sequester, sexual, SHTG, signature, singly, slightly, speaker, speaking, spike, steadily, strained, summer, surgical, surrendered, Switzerland, symptom, symptomatic, talent, Taxanomy, Taxonmy, TCT, tension, text, timeframe, tissue, tolderated, tomography, town, traditional, Transcatheter, treble, TRIAGE, undergone, underwent, unrealized, unscheduled, upholding, uptake, usage, vaccinated, VASEPA, vast, VAZKEPA, viral, widespread, witnessed, workforce, worsened, worsensed, worst, writ, wrong, Zug

Removed: abandon, abnormally, Acasti, acceleration, aggressively, amounted, attractive, BCF, bifurcation, bond, bridge, cancelled, CaPre, classification, concomitantly, contingency, conversion, Covenant, dedicate, Deed, default, dismissal, Docket, domain, encumber, entirety, existed, expensing, feasibility, formed, generation, host, house, inclusive, initiating, injunctive, instituted, issuable, krill, largely, leased, mandatorily, marked, maturing, Medica, membrane, memorandum, morbidity, Neptune, Nisshin, notified, notifying, partnering, perfected, pertaining, plasticity, prefer, prepay, preserving, pretrial, privately, provisional, PTAB, ran, recalculated, reclassification, reclassified, refinement, remedy, representation, rescinding, restate, send, shortfall, speculative, subscribed, Subtopic, Tariff, training, transition, unchanged, uncured, USITC, vulnerability, warrant, wholly

From filing 10-K 2020 FY